Chugai Pharmaceutical
CompanyJapan
Chugai Pharmaceutical develops one asset, approved (tocilizumab in Arthritis, Juvenile). Mostly antibody acting on inflammation and IL6R; based in Japan.
- 1
- Asset
- Furthest stage
- Approved
- 17
- Trials
- 0
- Signals
Pipeline
1Blocks interleukin-6 receptor signaling to reduce inflammation.
Approved, Antibody, Inflammation, IL6R, Arthritis, Juvenile, Arthritis, Juvenile Rheumatoid
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials32
- Integrity notices1
- Similar companies6